Mozambique African Region
I. Epidemiological pro le Population (UN Population Division) 2017 % Parasites and vectors High transmission (>1 case per 1000 population) 29.7M 100 Major plasmodium species: P.falciparum: 100 (%) , P.vivax: 0 (%) Low transmission (0-1 case per 1000 population) 0 - Major anopheles species: An. funestus, An. gambiae, An. arabiensis Malaria free (0 cases) 0 - Total 29.7M
Reported cases and deaths Estimates Reported con rmed cases (health facility): 8 921 081 Estimated cases: 10M [7.4M, 13.6M] Con rmed cases at community level: 971 520 Con rmed cases from private sector: - Reported deaths: 1114 Estimated deaths: 14.7K [12.2K, 17.2K]
II. Intervention policies and strategies Yes/ Year Intervention Policies/Strategies Medicine Year adopted No adopted Antimalaria treatment policy ITN ITNs/LLINs distributed free of charge Yes 2003 First-line treatment of uncon rmed malaria AL 2004 ITNs/LLINs distributed to all age groups Yes 2009 First-line treatment of P. falciparum AL 2004 IRS IRS is recommended Yes 2003 For treatment failure of P. falciparum - - DDT is used for IRS Yes 2006 Treatment of severe malaria AS, QN 2004 Larval control Use of Larval Control No Treatment of P. vivax - - IPT IPT used to prevent malaria during pregnancy Yes 2006 Dosage of primaquine for radical treatment of P. vivax Diagnosis Patients of all ages should receive diagnostic test Yes 2009 Type of RDT used P.f only Malaria diagnosis is free of charge in the public sector Yes 2005 Therapeutic ef cacy tests (clinical and parasitological failure, %) Treatment ACT is free for all ages in public sector Yes 2005 Medicine Year Min Median Max Follow-up No. of studies Species has AL 2011-2015 0 3.1 5.8 28 days 9 P. falciparum never The sale of oral artemisinin-based monotherapies (oAMTs) - AS+AQ 2011-2012 0 0 1.4 28 days 3 P. falciparum been allowed Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (2017) Single dose of primaquine (0.25 mg base/kg) is used as No - Insecticide class Years (%) sites1 Vectors2 Used3 gametocidal medicine for P. falciparum Carbamates 2010-2017 15.52% (58) An. funestus s.l., An. gambiae s.l. No Primaquine is used for radical treatment of P. vivax No - Organochlorines 2010-2017 14.06% (64) An. gambiae s.l. No G6PD test is a requirement before treatment with primaquine No - Organophosphates 2011-2017 0% (50) - Yes Directly observed treatment with primaquine is undertaken No - Pyrethroids 2010-2017 48.68% (76) An. funestus s.l., An. gambiae s.l. Yes System for monitoring of adverse reaction to antimalarials exists Yes 2002 1Percent of sites for which resistance con rmed and total number of sites that reported data (n) Surveillance ACD for case investigation (reactive) No - 2Principal vectors that exhibited resistance ACD at community level of febrile cases (pro-active) No - 3Class used for malaria vector control in 2017 Mass screening is undertaken No - Uncomplicated P. falciparum cases routinely admitted No - Uncomplicated P. vivax cases routinely admitted No - Case and foci investigation undertaken No Case reporting from private sector is mandatory No -
III. Charts Sources of nancing Government expenditure by intervention in 2017
250M
200M
150M
100M Contribution($USm)
50M
0M
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Insecticides & spray materials ITNs Diagnostic testing Others WHO/UNICEF USAID/PMI Worldbank (USD) Antimalarial medicines Monitoring and evaluation Global Fund (USD) Government contribution Human resources & technical assistance Management and other costs
IV. Coverage Coverage of ITN and IRS Cases tested and treated in public sector
100 100
75 75
50 (%) 50 Population 25
25
0
0 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Suspected cases tested Antimalarials distributed vs reported cases ACTs distributed vs reported P. f. cases % of households >= 1 ITN (Modelled) At risk protected with IRS Primaquine distributed vs reported P. v. cases % of the population who slept under an ITN the previous night (survey) % <5 fever cases who had a finger/ heel stick (survey) % of the population with access to an ITN (survey) ACTs as % of all antimalarials received by <5 (survey)
Source: AIS 2015, DHS 2011, MICS 2008, Other Nat.* Source: AIS 2015, DHS 2011, MICS 2008, Other Nat.* V. Impact Cases treated Test positivity
100% 100%
75% 75%
50% (%) 50% Tests (%)
25% 25%
0% 0%
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 % fever cases <5 seeking treatment at public HF (survey) Reporting completeness Slide positivity rate RDT positivity rate
Source: AIS 2015, DHS 2011
V. Impact Con rmed malaria cases per 1000 and ABER Malaria admissions and deaths
500 100 800k 8k
400 80 600k 6k Deaths
300 60 ABER (%)
400k 4k Admissions 200 40 Cases per 1000
200k 2k
100 20
0k 0k 0 0
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Admissions (all species) Admissions (P. vivax)) Deaths (all species) ABER Cases(all species) Cases (P. vivax) Deaths (P. vivax))
World Malaria Report 2018